Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
27 mei 2010 - 08:00
Statutaire naam
Pharming Group N.V.
Titel
PHARMING INITIATES EQUITY FUNDRAISING
Bericht
Leiden, The Netherlands, May 27, 2010. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) announced on April 22, 2010 to investigate the possibilities of attracting additional funding. Today, Pharming announces that it has received a number of pre-commitments from existing and new shareholders to participate in an intended equity offering of up to €12 million, by means of a private placement with institutional investors and qualifying investors who subscribe for a minimum amount of €50,000.
The net proceeds of such offering will be used for corporate activities, most notably for the ongoing regulatory approval processes and start of commercialization of Rhucin for the treatment of Hereditary Angioedema, and selective development of subsequent indications of rhC1 inhibitor.
Pharming expects to be able to make further announcements on the intended offering shortly.
Gerelateerde downloads
Datum laatste update: 11 januari 2026